NIPENT

This brand name is authorized in United States. It is also authorized in France, Ireland, Malta, Spain, UK.

Active ingredients

The drug NIPENT contains one active pharmaceutical ingredient (API):

1	Pentostatin UNII 395575MZO7 - PENTOSTATIN
	Pentostatin is a potent transition state inhibitor of the enzyme adenosine deaminase. The greatest activity of ADA is found in cells of the lymphoid system with T-cells having higher activity than B-cells and T-cell malignancies higher ADA activity than B-cell malignancies. Pentostatin has been shown to have activity against a variety of lymphoid malignancies, but is most active against indolent cancers with lower ADA concentration, such as hairy cell leukaemia.
	Read more about Pentostatin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
NIPENT Powder for solution for injection/infusion	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L01XX08	Pentostatin	L Antineoplastic and immunomodulating agents → L01 Antineoplastic agents → L01X Other antineoplastic agents → L01XX Other antineoplastic agents
Discover more medicines within L01XX08

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
ES	Centro de información online de medicamentos de la AEMPS	59993
FR	Base de données publique des médicaments	67322542
GB	Medicines & Healthcare Products Regulatory Agency	46350
MT	Medicines Authority	AA505/04502
US	FDA, National Drug Code	0409-0801